Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Ficker (Herzogenaurach, Germany). Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. 3416

Member's Comments

No comment yet.

Related content which might interest you: Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 The use of impulse oscillometry (IOS) in the differentiation of bronchiectasis and emphysema in patients with alpha1 antitrypsin deficiency (α1-ATD) Source: Annual Congress 2004 - Airway resistance: application and technique Year: 2004 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Patterns of exacerbations in alpha 1 antitrypsin deficiency (AATD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Epithelial cell biology Year: 2010 Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Alpha-1 antitrypsin COPD phenotypes are clinically more valid when defined by LLN rather than percent of predicted Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Alpha-1 antitrypsin deficiency in COPD patients: Time to count it in! Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 501s Year: 2003 Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content Year: 2018 Mortality versus FEV1, KCO and CT lung density measured at baseline in the UK alpha-1-antitrypsin deficiency assessment programme Source: Eur Respir J 2001; 18: Suppl. 33, 91s Year: 2001 Prevalence of mutations in the alpha 1 antitrypsin gene in patients with pulmonary emphysema Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 Specific airway resistance as a marker of early disease in alpha-1 antitrypsin deficiency Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008